Nov 2, 2022, 10:15 AM by

Vaxess Technologies, Inc., a life sciences company developing a shelf-stable, sustained-release vaccine patch, today announced the closing of its Series B funding.

Nov 2, 2022, 10:15 AM by

Nov 2, 2022, 10:14 AM by

Nov 2, 2022, 10:11 AM by

BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas.

Nov 2, 2022, 10:11 AM by

Owing to the continuously upgraded synthesis technologies and analytical abilities, BOC Sciences has performed well in the polymer industry, serving the community with a comprehensive product portfolio and valuable technical support.

Nov 2, 2022, 10:10 AM by

BOC Sciences provides global customers with a range of high-quality stable isotope labeling compounds for biomedical research. It recently announced the availability of labeled carbohydrates, arousing an enthusiastic response from the market.

Nov 2, 2022, 10:10 AM by

BOC Sciences announces support for antibody-drug conjugate (ADC) development, registration, and release by providing comprehensive analysis and characterization technologies.

Nov 2, 2022, 10:09 AM by

Nov 2, 2022, 09:59 AM by

Nov 2, 2022, 09:58 AM by

Nov 2, 2022, 09:54 AM by

Nov 2, 2022, 01:00 AM by User Not Found

Bio-IT World | Best practice surveillance protocols for seven diseases caused by group A Streptococcus (strep A) were recently released, and public health researchers are now actively working to identify several key sentinel sites to implement them. Harmonizing case definitions and the surveillance methodologies is a key step in accelerating development of a safe, effective, and affordable strep A vaccine to prevent these diseases.

Nov 1, 2022, 10:38 AM by

BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.

Nov 1, 2022, 10:37 AM by

Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer

Nov 1, 2022, 10:28 AM by

Nov 1, 2022, 10:27 AM by

Nov 1, 2022, 10:26 AM by

Nov 1, 2022, 10:06 AM by

Nov 1, 2022, 10:06 AM by

Nov 1, 2022, 10:05 AM by